Cantor Fitzgerald raised the firm’s price target on Five9 (FIVN) to $57 from $46 and keeps an Overweight rating on the shares. Give9 reported strong Q4 results with top-line growth accelerating, driven by momentum in large deals and bookings growing sequentially, the analyst tells investors in a research note. Top-line guidance for calendar 2025 implies just over 9%, and embeds prudent conservatism but also headwinds from the ramp of the final stages of the multi-year mega deal in healthcare contact in calendar 2024, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FIVN:
- Five9’s Strategic AI Positioning and Financial Growth Make It a Compelling Buy, Says Analyst David Hynes
- Five9’s Strong Revenue Growth and AI Integration Bolster Buy Rating
- Five9 price target raised to $48 from $46 at Morgan Stanley
- Five9 price target raised to $53 from $46 at Piper Sandler
- Five9 price target raised to $60 from $55 at Barclays